Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Addition of Perioperative Durvalumab to Neoadjuvant Chemo Generates Survival Benefits in Cisplatin-Eligible MIBC

September 15th 2024

NIAGARA was the first phase 3 study to evaluate perioperative immunotherapy plus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer.

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in Early TNBC

September 15th 2024

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.

Myeloma Molecular Profiling Reveals Unique Copy Number and Expression Subtypes

September 13th 2024

Findings from a molecular analysis of the CoMMpass study identified copy number and expression subtypes of high-risk, newly diagnosed multiple myeloma.

utDNA Could Provide Noninvasive Tool for MRD Detection Prior to Repeat TURBT in High-Risk NMIBC

September 13th 2024

Joshua Linscott, MD, PhD, discusses the use of urinary cell-free tumor DNA for MRD detection prior to repeat resection in high-risk NMIBC.

Clinical Development of Gamma-Delta T-Cell Therapy INB-400 Paused in Glioblastoma

September 11th 2024

The phase 2 trial of the gamma-delta T-cell therapy INB-400 plus temozolomide in patients with newly diagnosed GBM has suspended enrollment.

Bria-IMT Plus Checkpoint Inhibition Maintains Favorable OS in Metastatic Breast Cancer

September 11th 2024

Updated data from a phase 1/2 study showed positive overall survival outcomes with Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer.

Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure

September 10th 2024

Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.

Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC

September 10th 2024

Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.

FDA Approval of Amivantamab Plus Lazertinib Builds Upon Success of First-Line TKIs in Advanced EGFR-Mutant NSCLC

September 10th 2024

Joshua K. Sabari, MD, discusses the significance of the FDA approval of first-line amivantamab plus lazertinib for patients with EGFR-mutant NSCLC.

Sacituzumab Govitecan Generates Responses With Manageable Safety Profile in ES-SCLC

September 9th 2024

Treatment with sacituzumab govitecan in the second-line setting yielded antitumor activity in patients with extensive-stage small cell lung cancer.

Early Data Show Complete Responses With Elraglusib Combination in Ewing Sarcoma

September 9th 2024

Elraglusib plus chemotherapy generated early signals of antitumor activity in pediatric patients with relapsed/refractory Ewing and Ewing-related sarcomas.

RLY-2608/Fulvestrant Yields Early Clinical Activity in PI3Kα-Mutated, HR+/HER2–Breast Cancer

September 9th 2024

RLY-2608 plus fulvestrant generated clinically meaningful PFS outcomes in PI3Kα-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

FDA Approves TruSight Oncology Comprehensive Assay As Pan-Tumor Companion Diagnostic

September 9th 2024

The TruSight Oncology Comprehensive Assay has been approved by the FDA with companion diagnostic claims in NSCLC and NTRK-positive solid tumors.

Real-World Outpatient CAR T-Cell Administration Insights Show Improved Safety and Feasibility in NHL

September 9th 2024

Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.

Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC

September 6th 2024

Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.

Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC

September 6th 2024

Moshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.

FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma

September 5th 2024

The FDA has granted fast track designation to the MCR1-targeted theranostic ligand VMT01 for unresectable or metastatic melanoma.

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma

September 5th 2024

Certepetide has been granted orphan drug designation by the FDA for the treatment of patients with cholangiocarcinoma.

Blinatumomab May Be an Effective Alternative to Consolidation Chemotherapy in Down Syndrome B-ALL

September 3rd 2024

Sujith Samarasinghe, BSc, MBBS, MRCPCH, FRCPath, PhD, discusses the use of blinatumomab in children with Down syndrome acute lymphoblastic leukemia.

Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma

August 31st 2024

Jennifer R. Eads, MD, explains the relevance of negative results from the ECOG-ACRIN EA2174 trial in esophageal/gastroesophageal junction adenocarcinoma.